Switzerland: Oviva raises US$21m Series B

Oviva, a digital provider of Type 2 diabetes treatment in Europe, has raised US$21m in Series B funding to expand across Europe. “The new financing allows us to roll out our uniquely effective solution to large patient populations rapidly across Europe and further develop the underlying technology to better address patients’ unmet needs,” said chief executive…

You must be a HMI Subscriber to view this content. Please log in or subscribe below.

Subscribe Now »